# Pseudohypoparathyroidism During Pregnancy:

# A Rare Disease with Significant Diagnostic, Clinical and Hereditary Consequences for Mother and Neonate

Sara J. Hitt, MS2<sup>1</sup>; Claire McCarthy, MS3<sup>1</sup>; Renee Ricci DO<sup>2</sup>; Bethany Bowling MS3<sup>1</sup>; Anthony B. Royek MD<sup>2</sup>
1. Mercer University School of Medicine. 2. Memorial Health University Medical Center, Department of Obstetrics & Gynecology



## Background

- Pseudohypoparathyroidism (PHP) type 1b is a rare, genetically heterogenous condition due to abnormal methylations in the GNAS1 gene [1]. This leads to resistance to parathyroid hormone (PTH).
- Patients may also develop resistance to other hormones such as thyroid-stimulating hormone (TSH), calcitonin, and growth hormone-releasing hormone (GHRH).
- Patients with PHP typically suffer from hypocalcemia and hyperphosphatemia due to the oversecretion of PTH [1].
- During pregnancy, there are significant changes in calcium and active vitamin D homeostasis.
- Patients diagnosed with PHP require careful monitoring and frequent adjustments to pharmacological management due to changes in calcium and vitamin D requirements [2].
- Inadequate serum monitoring and treatment may result in fetal and neonatal hyperparathyroidism as well as an increased risk of neonatal hypoglycemia and respiratory depression.
- Due to the rarity of this disease, there is limited data discussing the management of PHP during pregnancy and birth.

#### **Case Presentation**

- A 27-year-old primigravida at 26 weeks EGA was referred to our high-risk OB clinic for maternal management of PHP type 1b and hypothyroidism.
- She was taking calcitriol capsules 0.25 mcg twice a day, vitamin D 1000 units daily, levothyroxine 25 mcg daily, and prenatal vitamins.
- Labs showed a free T4 at 0.53, intact PTH at 51, ionized calcium at 4.9, and phosphorus at 4.6. The patient's endocrinologist monitored calcium, phosphorus, and thyroid function tests frequently during pregnancy.
- At 35 weeks 4 days EGA, she presented to the clinic in preterm labor with painful contractions and vaginal bleeding. She was escorted to the labor and delivery unit for further obstetric management.

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated

# Case Presentation (continued)

- Although the endocrinologist expressed concern over the ability of the uterus to contract effectively, the patient progressed normally in labor and delivered a 2620g female neonate vaginally. Apgar scores were 8/9.
- The neonate was admitted to the NICU for observation and serial assessment of serum calcium and glucose.
- A neonatal hypoparathyroidism gene panel revealed:
- A sequence variant of the GCM2 gene associated with autosomal dominant hyperparathyroidism and autosomal recessive familial hypoparathyroidism
- A duplication within the GNAS locus associated with maternally-inherited autosomal dominant pseudohypoparathyroidism type 1a, type 1b and type 1c.
- The patient had an uneventful postpartum course and was discharged home on postpartum day 2.
- The neonate had mild hypocalcemia and high parathyroid hormone 2 days after birth and a pediatric endocrinologist was consulted. After a 4-day NICU admission, the neonate was discharged home.




Figure 1. Imprinting defect seen in GNAS1 gene of affected mothers with PHP type 1b. [3]

### Conclusion

- •This case highlights the importance of multidisciplinary care and collaboration in pregnancies complicated by PHP.
- •Due to the nature of this disorder, frequent monitoring and adjustments to medical management are necessary to accommodate the physiological changes and demands during pregnancy.
- •The patient in this case was able to have a successful vaginal delivery, uneventful postpartum course, and short NICU admission for her neonate.
- •Multidisciplinary management improves outcomes by limiting adverse events, such as maternal and neonatal metabolic derangements.

#### References

- •1. Linglart, A., Levine, M. A., & Jüppner, H. (2018). Pseudohypoparathyroidism. Endocrinology and metabolism clinics of North America, 47(4), 865–888. https://doi.org/10.1016/j.ecl.2018.07.011
- •2. Marcucci, G., Altieri, P. et al "Hypoparathyroidism Working Group" affiliated to the Italian Society of Endocrinology (S.I.E.) (2021). Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. Orphanet journal of rare diseases, 16(1), 421. https://doi.org/10.1186/s13023-021-02053-3
- •3. Jan de Beur, S. M., & Levine, M. A. (2016). Pseudohypoparathyroidism an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/pseudohypoparathyroidism

